ESTRO 2024 - Abstract Book

S1131

Clinical - Haematology

ESTRO 2024

Keywords: Stomach, MALT lymphoma, VMAT

References:

1.

National

Comprehensive

Cancer

Network.

B-Cell

Lymphomas

(Version

5.2023).

https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed October 4, 2023.

2. Daniel Rolf, Gabriele Reinartz, Stephan Rehn, Christopher Kittel, Hans Theodor Eich. Development of Organ Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma. Cancers (Basel) 2022;14(4):873.

3. Chelsea C Pinnix CC, Jillian R Gunther, Sarah A Milgrom et al. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019;104(2):447-455.

288

Proffered Paper

Mycosis Fungoides with Large Cell Transformation: Radiotherapy Dose Response and Patient Outcomes

Philippa Johnstone 1 , Martin Higgins 2,1 , H Miles Prince 3,4 , Stephen Lade 5 , Michael Fahey 6 , Christopher McCormack 7 , Carrie van der Weyden 3,4 , Friyana K Bhabha 7 , Odette Buelens 3 , Piers Blombery 3,5 , Belinda A Campbell 1,4,5 1 Peter MacCallum Cancer Centre, Radiation oncology, Melbourne, Australia. 2 Cork University Hospital, Radiation oncology, Cork, Ireland. 3 Peter MacCallum Cancer Centre, Department of Haematology, Melbourne, Australia. 4 University of Melbourne, Department of Oncology, Melbourne, Australia. 5 Peter MacCallum Cancer Centre, Department of Clinical Pathology, Melbourne, Australia. 6 Peter MacCallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Melbourne, Australia. 7 Peter MacCallum Cancer Centre, Department of Surgical Oncology, Melbourne, Australia

Purpose/Objective:

Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphoma (CTCL), with a protracted clinical course and usually associated with a multi-line treatment journey. Large Cell Transformation of Mycosis Fungoides (LCTMF) is a rare, but significant complication, and usually confers a much poorer prognosis. 1 Radiotherapy is commonly utilised as an effective local treatment for LCTMF as either definitive or palliative therapy. However, to date, there is a paucity of published dose-response data for LCTMF to guide radiotherapy prescription in clinical practice.

Material/Methods:

In this retrospective study, patients with a proven diagnosis of LCTMF, between 1/1/1990 to 01/10/2021, and treated with radiotherapy at the Peter MacCallum Cancer Centre were included. LCT was confirmed histologically when